SG52834A1 - 11- (substituted phenyl) - estra-4, 9-diene derivatives - Google Patents

11- (substituted phenyl) - estra-4, 9-diene derivatives

Info

Publication number: SG52834A1
Authority: SG; Singapore
Prior art keywords: estra; substituted phenyl; diene derivatives; diene; derivatives
Prior art date: 1995-08-17

Application number

SG1996010458A

Other languages

English (en)

Inventor

Ronald Gebhard

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-17

Filing date

1996-08-14

Publication date

1998-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG52834(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-14 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1998-09-28 Publication of SG52834A1 publication Critical patent/SG52834A1/en

Links

-1 11- (substituted phenyl) - estra-4, 9-diene Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG1996010458A 1995-08-17 1996-08-14 11- (substituted phenyl) - estra-4, 9-diene derivatives SG52834A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP95202229		1995-08-17

Publications (1)

Publication Number	Publication Date
SG52834A1 true SG52834A1 (en)	1998-09-28

Family

ID=8220570

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG1996010458A SG52834A1 (en)	1995-08-17	1996-08-14	11- (substituted phenyl) - estra-4, 9-diene derivatives

Country Status (25)

Country	Link
US (1)	US6011025A (fr)
EP (1)	EP0763541B1 (fr)
JP (1)	JP3977462B2 (fr)
KR (1)	KR100445376B1 (fr)
CN (1)	CN1129602C (fr)
AR (1)	AR003982A1 (fr)
AT (1)	ATE182596T1 (fr)
AU (1)	AU711369B2 (fr)
BR (1)	BR9603429A (fr)
CA (1)	CA2182771C (fr)
CZ (1)	CZ287740B6 (fr)
DE (1)	DE69603425T2 (fr)
DK (1)	DK0763541T3 (fr)
ES (1)	ES2137625T3 (fr)
GR (1)	GR3031116T3 (fr)
HU (1)	HU229023B1 (fr)
IL (1)	IL118974A (fr)
NO (1)	NO306257B1 (fr)
NZ (1)	NZ299181A (fr)
PL (1)	PL183468B1 (fr)
RU (1)	RU2135514C1 (fr)
SG (1)	SG52834A1 (fr)
TR (1)	TR199600664A2 (fr)
TW (1)	TW464654B (fr)
ZA (1)	ZA966555B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0903146A1 (fr)	1997-09-23	1999-03-24	Applied Research Systems ARS Holdings N.V.	21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
AU747956B2 (en) *	1997-10-06	2002-05-30	Board Of Trustees Of The Leland Stanford Junior University	Methods for treating psychosis associated with glucocorticoid related dysfunction
EP1726307A3 (fr) *	1997-10-06	2007-04-04	The Board Of Trustees Of The Leland Stanford Junior University	Methodes de traitement de la psychose associee a un dysfonctionnement lie aux glucocorticoides
IL139672A (en)	1998-05-15	2005-11-20	Univ Leland Stanford Junior	Glucocorticoid receptor antagonists for the tretment of dementia
ATE246703T1 (de) *	1999-04-06	2003-08-15	Akzo Nobel Nv	Oral wirksame 7-alpha-alkyl androgene
MXPA03007261A (es) *	2001-02-14	2006-03-09	Abbott Lab	Moduladores del receptor de glucocorticoides.
EP1285927A3 (fr)	2001-08-16	2005-06-29	Schering Aktiengesellschaft	Utilisation d'antagonistes du récepteur glucocorticoide pour la prévention et traitement des maladies de la fonction reproductive masculine
DE60230936D1 (de) *	2001-10-26	2009-03-05	Organon Nv	Verwendung von (11beta, 17beta)-11-(1,3-Benzodioxol-5-yl)-17-Hydroxy-17-(1-Propinyl)-estra-4,9-dien-3-on zur Behandlung von schweren Depressionen
AU2002366217A1 (en)	2001-11-23	2003-06-10	Akzo Nobel N.V.	Treatment of major depressive disorder using glucocorticoid receptor antagonists
CA2504751C (fr) *	2002-11-05	2013-02-05	Corcept Therapeutics, Inc.	Procedes servant a traiter le reflux gastro-oesophagien pathologique
JP2006516651A (ja) *	2003-02-04	2006-07-06	コーセプトセラピューティクス，インコーポレイテッド	産後精神病の処置のための抗糖質コルチコイド
TW200820977A (en)	2006-08-08	2008-05-16	Organon Nv	Use of glucocorticoid receptor antagonists for treatment of infectious conditions
WO2012106514A2 (fr) *	2011-02-03	2012-08-09	Pop Test Cortisol Llc	Système et méthode de diagnostic et de traitement
US20120245552A1 (en) *	2011-03-23	2012-09-27	Pop Test Cortisol Llc	Combination Therapy
US8865693B2 (en)	2011-03-31	2014-10-21	Pop Test Cortisol Llc	Prevention of infection
WO2012145258A1 (fr) *	2011-04-18	2012-10-26	Pop Test Cortisol Llc	Traitement contre la perte des cheveux
US8986677B2 (en)	2012-07-30	2015-03-24	Pop Test Cortisol Llc	Therapeutic compositions and methods
US9878138B2 (en)	2014-06-03	2018-01-30	Pop Test Abuse Deterrent Technology Llc	Drug device configured for wireless communication
AU2016226451B2 (en) *	2015-03-02	2019-12-19	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
EP3273983B1 (fr) *	2015-03-23	2021-05-05	Evestra, Inc.	Nouveaux agents cytotoxiques qui ciblent préférentiellement le facteur d'inhibition de la leucémie (lif) pour le traitement de tumeurs malignes et comme nouveaux agents contraceptifs
US10610534B2 (en)	2015-03-30	2020-04-07	Corcept Therapeutics, Inc.	Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3400233B1 (fr) *	2015-08-03	2025-10-22	Pop Test Oncology LLC	Compositions pharmaceutiques et méthodes
WO2017023694A1 (fr) *	2015-08-03	2017-02-09	Pop Test Oncology Llc	Compositions pharmaceutiques et méthodes
KR20180052120A (ko)	2015-08-13	2018-05-17	코어셉트 쎄라퓨틱스, 잉크.	Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
WO2017112904A1 (fr)	2015-12-23	2017-06-29	Oric Pharmaceuticals, Inc.	Inhibiteurs de récepteurs glucocorticoïdes
EP3394078A4 (fr) *	2015-12-23	2019-11-27	Oric Pharmaceuticals, Inc.	Inhibiteurs de récepteurs glucocorticoïdes
JP6995757B2 (ja) *	2015-12-23	2022-01-17	オリックファーマシューティカルズ，インク．	グルココルチコイド受容体の阻害剤
JP6765443B2 (ja)	2016-01-19	2020-10-07	コーセプトセラピューティクス，インコーポレイテッド	異所性クッシング症候群の鑑別診断
NZ753142A (en) *	2016-10-07	2020-08-28	Oric Pharmaceuticals Inc	Inhibitors of glucocorticoid receptor
WO2018236749A2 (fr)	2017-06-20	2018-12-27	Corcept Therapeutics, Inc.	Méthodes de traitement des tumeurs neuro-épithéliales à l'aide de modulateurs sélectifs du récepteur de glucocorticoïdes
EP4653047A3 (fr)	2019-03-18	2026-02-18	Nieman, Lynnette K.	Mifepristone destinée à être utilisée pour améliorer la sensibilité à l'insuline

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) *	1982-03-01	1986-02-14	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
US4780461A (en) *	1983-06-15	1988-10-25	Schering Aktiengesellschaft	13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3625315A1 (de) *	1986-07-25	1988-01-28	Schering Ag	11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
IE60780B1 (en) *	1987-01-23	1994-08-10	Akzo Nv	New 11-aryl steroid derivatives
DE3708942A1 (de) *	1987-03-18	1988-09-29	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) *	1987-05-19	1988-12-01	Schering Ag	19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) *	1987-07-16	1989-01-26	Schering Ag	11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3822770A1 (de) *	1988-07-01	1990-01-04	Schering Ag	13-alkyl-11ss-phenylgonane
DE59010853D1 (de) *	1989-08-04	1998-12-03	Schering Ag	11 Beta-Aryl-gona-4,9-dien-3-one
WO1995004536A1 (fr) *	1993-08-04	1995-02-16	Akzo Nobel N.V.	Steroïdes antiglucocorticoïdes destines au traitement de troubles associes a l'anxiete
EP0683172B1 (fr) *	1994-05-19	1997-08-13	Akzo Nobel N.V.	Dérivés 11,21-bisphényle-19-nor-pregnanes

1996
- 1996-07-29 IL IL11897496A patent/IL118974A/en not_active IP Right Cessation
- 1996-08-01 ZA ZA9606555A patent/ZA966555B/xx unknown
- 1996-08-06 CA CA002182771A patent/CA2182771C/fr not_active Expired - Fee Related
- 1996-08-12 JP JP21282496A patent/JP3977462B2/ja not_active Expired - Fee Related
- 1996-08-13 CZ CZ19962386A patent/CZ287740B6/cs not_active IP Right Cessation
- 1996-08-13 DE DE69603425T patent/DE69603425T2/de not_active Expired - Lifetime
- 1996-08-13 EP EP96202273A patent/EP0763541B1/fr not_active Expired - Lifetime
- 1996-08-13 DK DK96202273T patent/DK0763541T3/da active
- 1996-08-13 ES ES96202273T patent/ES2137625T3/es not_active Expired - Lifetime
- 1996-08-13 AT AT96202273T patent/ATE182596T1/de active
- 1996-08-14 KR KR1019960033671A patent/KR100445376B1/ko not_active Expired - Fee Related
- 1996-08-14 SG SG1996010458A patent/SG52834A1/en unknown
- 1996-08-14 BR BR9603429A patent/BR9603429A/pt not_active IP Right Cessation
- 1996-08-15 TR TR96/00664A patent/TR199600664A2/xx unknown
- 1996-08-15 NZ NZ299181A patent/NZ299181A/en not_active IP Right Cessation
- 1996-08-16 PL PL96315733A patent/PL183468B1/pl not_active IP Right Cessation
- 1996-08-16 NO NO963427A patent/NO306257B1/no not_active IP Right Cessation
- 1996-08-16 RU RU96115774/04A patent/RU2135514C1/ru not_active IP Right Cessation
- 1996-08-16 HU HU9602269A patent/HU229023B1/hu not_active IP Right Cessation
- 1996-08-16 AU AU62119/96A patent/AU711369B2/en not_active Ceased
- 1996-08-16 AR ARP960104036A patent/AR003982A1/es unknown
- 1996-08-16 CN CN96111830A patent/CN1129602C/zh not_active Expired - Fee Related
- 1996-08-22 TW TW085110266A patent/TW464654B/zh not_active IP Right Cessation
1997
- 1997-09-22 US US08/935,360 patent/US6011025A/en not_active Expired - Lifetime
1999
- 1999-08-31 GR GR990402198T patent/GR3031116T3/el unknown

Also Published As

Publication number	Publication date
KR970010784A (ko)	1997-03-27
PL183468B1 (pl)	2002-06-28
IL118974A0 (en)	1996-10-31
HUP9602269A3 (en)	1997-12-29
IL118974A (en)	2001-09-13
PL315733A1 (en)	1997-03-03
TR199600664A2 (tr)	1997-03-21
AR003982A1 (es)	1998-09-30
CZ287740B6 (en)	2001-01-17
RU2135514C1 (ru)	1999-08-27
JP3977462B2 (ja)	2007-09-19
NZ299181A (en)	1997-09-22
ZA966555B (en)	1997-02-19
DE69603425T2 (de)	2000-01-20
AU711369B2 (en)	1999-10-14
EP0763541A1 (fr)	1997-03-19
NO963427L (no)	1997-02-18
DE69603425D1 (de)	1999-09-02
GR3031116T3 (en)	1999-12-31
AU6211996A (en)	1997-02-20
CA2182771A1 (fr)	1997-02-18
CA2182771C (fr)	2007-04-24
JPH09104696A (ja)	1997-04-22
US6011025A (en)	2000-01-04
KR100445376B1 (ko)	2004-11-08
HU229023B1 (en)	2013-07-29
MX9603476A (es)	1997-07-31
BR9603429A (pt)	1998-05-12
NO963427D0 (no)	1996-08-16
HU9602269D0 (en)	1996-10-28
ES2137625T3 (es)	1999-12-16
DK0763541T3 (da)	2000-02-28
TW464654B (en)	2001-11-21
CN1129602C (zh)	2003-12-03
NO306257B1 (no)	1999-10-11
CZ238696A3 (en)	1997-05-14
EP0763541B1 (fr)	1999-07-28
CN1147520A (zh)	1997-04-16
HK1002010A1 (en)	1998-07-24
ATE182596T1 (de)	1999-08-15
HUP9602269A2 (en)	1997-04-28

Publication	Publication Date	Title
GR3031116T3 (en)	1999-12-31	11-(Substituted phenyl)-estra-4,9-diene derivatives
ZA961444B (en)	1997-08-25	Pyrazolylbenzoyl derivatives.
ZA9884B (en)	1998-07-08	16-Hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
ZA9710573B (en)	1998-06-10	New substituted pyrazole derivatives.
HU9700126D0 (en)	1997-02-28	2-oxo- and 2-thio-1,2-dihydroquinolinyl-oxazotidinone derivatives
DE69628446D1 (en)	2003-07-03	Polycarbonatharz, vernetztes polycarbonatharz und elektrophotographischer photorezeptor
ZA961449B (en)	1997-08-25	Isoxazolylbenzoyl derivatives.
IL134220A0 (en)	2001-04-30	6,9-bridged erythromycin derivatives
IL126624A0 (en)	1999-08-17	3-descladinose-2, 3-anhydroerythromycin derivatives
IL134996A0 (en)	2001-05-20	6,11-bridged erythromycin derivatives
ZA969973B (en)	1998-05-27	2-thioxo-imidazolidin-4-one derivatives.
GB9411088D0 (en)	1994-07-27	Hydroxylamine derivatives
ZA966048B (en)	1998-01-16	Piperazine derivatives.
ZA989431B (en)	1999-04-19	D-homo-9,10-secochloldesta-23-yne-3,25-diol derivatives
HU9600871D0 (en)	1996-05-28	New 2,3-benzodiazepine derivatives
ZA974953B (en)	1997-12-08	Substituted pyrazolylpyrazole derivatives.
ZA967741B (en)	1998-03-13	Diarylalkenylamine derivatives.
PL326837A1 (en)	1998-10-26	25-hydroxy-16-ene-26, 27-bishomocholecarctiferoles
ZA962821B (en)	1997-10-09	4-indolylpiperazinyl derivatives.
ZA967357B (en)	1998-03-02	Pyrazol-4-ylbenzoyl derivatives.
ZA983902B (en)	1999-11-08	Erythromycin derivatives.
ZA964034B (en)	1997-11-21	N-aminopyridone derivatives.
HK1023349A (en)	2000-09-08	16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
ZA968953B (en)	1997-07-30	24-homo-26,27-hexafluoro-cholecalciferols
HUP0302187A3 (en)	2012-02-28	11-(substituted phenyl)-estra-4,9-diene derivatives, their production and use as medicament